Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

Study Questions:

What is the risk of discontinuation of rivaroxaban in patients being treated for thromboembolic prophylaxis in the setting of atrial fibrillation (AF)?